INMB (INmune Bio) Total Debt per Share: $0.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INMB INmune Bio Inc INMB
53 GF Score
Price $1.62
GF Value $1.80
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is INmune Bio Total Debt per Share?

INmune Bio INMB -6.90% 53 Total Debt per Share is $0.06 as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 53/100 and a GF Value™ of $1.80 (Modestly Undervalued). The stock has 5 warning signs investors should review.

$0.06 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. INmune Bio's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.06.

INmune Bio Total Debt per Share Historical Data

* Premium members only.

The historical data trend for INmune Bio's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio Total Debt per Share Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.85 0.58 0.02 0.04

INmune Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.04 0.04 0.06
INMB
53GF Score
INmune Bio Inc INMB
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

INmune Bio Total Debt per Share Calculation

INmune Bio's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.41+0.62)/26.59
=0.04

INmune Bio's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.81+0.70)/26.59
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.06 mean?
INmune Bio (INMB) has a Total Debt per Share of $0.06 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on INmune Bio and its competitors.
Is INmune Bio's Total Debt per Share too high?
INmune Bio's current Total Debt per Share is $0.06. Overall, INmune Bio has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Total Debt per Share compare to GRCE and NTRB?
INmune Bio's Total Debt per Share of $0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on INmune Bio and its competitors. INmune Bio's current Total Debt per Share is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.80, compared to a current price of $1.62 — trading 10% below its estimated fair value. The current Total Debt per Share is $0.06. INmune Bio's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For INmune Bio (INMB), the current Total Debt per Share is $0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.62 is trading 10% below its estimated GF Value™ of $1.80. GuruFocus considers INmune Bio to be Modestly Undervalued.

Key valuation signals for INMB:

  • Total Debt per Share: $0.06
  • GF Value™: $1.80 vs. price of $1.62 (10% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
53GF Score

Get the complete analysis for INMB

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.62
Price
$1.80
GF Value